This website is best viewed using the horizontal display on your tablet device.
This website is best viewed using the vertical display on your mobile device.
Analysis limitations: These analyses are exploratory in nature and definitive conclusions should not be drawn.
Efficacy data based on long-term follow-up analysis (median time from ABECMA infusion to data cutoff 27.3 months [range 24.1 to 33.1]; N=100). Data were generally consistent with the primary analysis. See ORR at primary analysis.
BMCA=B-cell maturation antigen; ISS=International Staging System; LCL=lower bound of 95% CI; MM=multiple myeloma; ORR=overall response rate; PI=proteasome inhibitor; TTNT=time to next treatment; UCL=upper bound of 95% CI.